Influence of growth hormone therapy on the occurrence of a second neoplasm in survivors of childhood cancer

2021 ◽  
Author(s):  
Thomas-Teinturier C ◽  
Oliver-Petit I ◽  
Pacquement H ◽  
Fresneau B ◽  
Allodji RS ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Childhood Cancer ◽  
Hormone Therapy ◽  
Growth Hormone Therapy ◽  
Second Neoplasm ◽  
Survivors Of Childhood Cancer

scholarly journals Influence of growth hormone therapy on the occurrence of a second neoplasm in survivors of childhood cancer

2020 ◽  
Vol 183 (4) ◽  
pp. 471-480 ◽  
Author(s):  
Cécile Thomas-Teinturier ◽  
Isabelle Oliver-Petit ◽  
Helene Pacquement ◽  
Brice Fresneau ◽  
Rodrigue Sétchéou Allodji ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Childhood Cancer ◽  
Case Control Study ◽  
Case Control ◽  
Gh Therapy ◽  
Second Neoplasm ◽  
Gh Treatment ◽  
Survivors Of Childhood Cancer ◽  
The Impact ◽  
Control Study

Context: Growth hormone (GH) deficiency is a common late effect of cranial irradiation. However, concerns have been raised that GH treatment might lead to an increased risk of a second neoplasm (SN). Objective: To study the impact of GH treatment on the risk of SN in a French cohort of survivors of childhood cancer (CCS) treated before 1986. Design and setting: Cohort study and nested case–control study. Participants: Of the 2852 survivors, with a median follow-up of 26 years, 196 had received GH therapy (median delay from cancer diagnosis: 5.5 years). Main outcome measures: Occurrence of SN Results: In total, 374 survivors developed a SN, including 40 who had received GH therapy. In a multivariate analysis, GH treatment did not increase the risk of secondary non-meningioma brain tumors (RR: 0.6, 95% CI: 0.2–1.5, P = 0.3), secondary non-brain cancer (RR: 0.7, 95% CI: 0.4–1.2, P = 0.2), or meningioma (RR: 1.9, 95% CI: 0.9–4, P = 0.09). Nevertheless, we observed a slight non-significant increase in the risk of meningioma with GH duration: 1.6-fold (95% CI: 1.2–3.0) after an exposure of less than 4 years vs 2.3-fold (95% CI: 0.9–5.6) after a longer exposure (P for trend = 0.07) confirmed by the results of a case–control study. Conclusion: This study confirms the overall safety of GH use in survivors of childhood cancer, which does not increase the risk of a SN. The slight excess in the risk of meningioma in patients with long-term GH treatment is non-significant and could be due to difficulties in adjustment on cranial radiation volume/dose and/or undiagnosed meningioma predisposing conditions.

Does growth hormone therapy increase the frequency of tumor recurrence in children with brain tumors?

1987 ◽  
Vol 116 (3_Suppl) ◽  
pp. S188-S189 ◽  
Author(s):  
K.P. RODENS ◽  
S.L. KAPLAN ◽  
M.M. GRUMBACH ◽  
W.M. TELLER
Keyword(s):  
Growth Hormone ◽  
Brain Tumors ◽  
Hormone Therapy ◽  
Tumor Recurrence ◽  
Growth Hormone Therapy

Growth hormone therapy in a child with severe short stature due to Miller-McKusick-Malvaux (3M) syndrome-2

2019 ◽  
Author(s):  
Sumudu Seneviratne ◽  
Deepthi de Silva ◽  
Emily Cottrell ◽  
Piumi Kuruppu ◽  
KSH de Silva ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Hormone Therapy ◽  
Short Stature ◽  
Growth Hormone Therapy ◽  
Severe Short Stature
Sign in / Sign up

Export Citation Format

Share Document